

ANNUAL UPDATES FROM ASH 2017:

Practice Changing Abstracts

CHICAGO, ILLINOIS

March 3, 2018

Course Director: Michael Bishop, MD

Director of the Hematopoietic Cellular Therapy Program
University of Chicago Medicine

NEW VENUE

University of Chicago

The Knapp Center for
Biomedical Discovery

900 East 57th St
Chicago, IL 60637



AT THE FOREFRONT

**UChicago
Medicine**

CHICAGOPOSTASH.COM

COURSE DESCRIPTION

Patients in medically underserved communities have limited access to subspecialty care. Community-based oncologists are well positioned to provide initial care for these patients, but often do not have the knowledge and confidence to manage difficult cases. According to the 2015 Community Health Needs Assessment, between 2006 and 2008, the City of Chicago experienced an annual average adjusted cancer mortality rate of 194.2 deaths per 100,000 individuals. Cancer mortality has decreased over the past decade in Cook County; the same trend is apparent both statewide and nationwide. Although both trends are decreasing, Cook County cancer related mortality is greater than the national average deaths per 100,000 individuals. Also, city of Chicago cancer mortality rates are higher than regional, state, and national cancer death rates. University experts in hematological cancers agree that we need to join our regional cancer community to lower our county and state mortality rate. Also, many local health professionals do not have the time or resources available to attend the annual updates from ASH 2017 conference where the latest scientific and clinical research in blood cancers is discussed, so they need a venue in which they can learn about these important updates.

Target Audience

This activity has been designed for physicians and other healthcare professionals interested in the treatment of hematologic cancers.

Learning Objectives

- Cite how understanding the biology of different types of leukemia has influenced treatment approaches;
- Describe next generation improvements in CAR T-cell therapies;
- Identify methods for integrating therapeutic advances into practice to improve current myeloma patient care;
- List current best practices in first and second line therapies for lymphoid malignancies;
- Name new technologies used for the treatment of hemophilia;
- Interpret how new scientific insights are informing the diagnosis and treatment of myelodysplastic syndromes and myeloproliferative neoplasms.

AGENDA | March 3, 2018

Faculty Disclosure

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Educational Grants/Commercial Support

A complete listing of commercial support received will be provided in the conference materials.

OPENING REMARKS

Sonali Smith, MD

8:00 – 8:30 am

Scientific Progress in Leukemias

Wendy Stock, MD

University of Chicago Medicine

8:30 – 9:00 am

Improving Cellular Therapy

Peter Riedell, MD

University of Chicago Medicine

9:00 – 9:30 am

BREAK

9:30 – 10:00 am

Continued Improvement in Treatment of Multiple Myeloma

Andrzej Jakubowiak, MD, PhD

University of Chicago Medicine

10:00 – 10:30 am

New Approaches to the Treatment of Lymphomas

Justin Kline, MD

University of Chicago Medicine

10:30 – 11:00 am

BREAK

11:00 – 11:30 am

Clinical Updates in Clotting Disorders

Kenneth Cohen, MD

University of Chicago Medicine

11:30 – 12:00 pm

New Scientific Insights into MDS and MPN

Olatoyosi Odenike, MD

University of Chicago Medicine

12:00 – 12:30 pm

Hematopoietic Cell Transplantation for Myeloma: What comes after High Dose Melphalan?

Guest Speaker

Sergio Giral, MD

Memorial Sloan Kettering

12:30 – 1:00 pm

Q & A

REGISTER TODAY

ChicagoPostAsh.com

ANNUAL UPDATES FROM ASH 2017: Practice Changing Abstracts

CHICAGO, ILLINOIS

March 3, 2018

Course Director: *Michael Bishop, MD*
Director of the Hematopoietic Cellular Therapy Program
University of Chicago Medicine

Accreditation Statement

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of **4.0 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for **AMA PRA Category 1 Credit™** from organizations accredited by the ACCME, please consult your professional licensing board.

Additional Information

For information regarding course registration, or course credit, contact Meeting Achievements at 219.465.1115 or email polly@meetingachievements.com

